U01DA064384), OUD (NCT04199728, NCT06639464, NCT06548490 and NCT06651177), and cocaine use disorder (NCT06252623), including an RCT in patients with cocaine use disorder and Human Immunodeficiency Virus infection (NCT06691243)
What Patients Need to Know Side effects: Similar to other GLP-1 drugsmostly nausea, vomiting, or digestive upset
Abernathy M
This disease affects approximately 23% of the population and is increasingly recognized as a systemic disorder
Do I stay on medication
A Hims & Hers spokesperson told Reuters the company does not expect any impact on its business from the FDAs proposal, saying, There are no GLP1s compounded by 503B facilities accessible through our platform, and 503B facilities should not currently be compounding GLP1s because they are not in shortage. Most telehealth companies use 503A pharmacies to fill their personalized compounded doses, said Rosalie Hoyle, a research scientist at health consultancy Avalere, adding the exclusion from the 503B bulks list may not operationally impact current compounding of GLP-1 drugs
